U.S., July 15 -- ClinicalTrials.gov registry received information related to the study (NCT07702461) titled 'Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists' on July 08.
Brief Summary: This study examines how adults who take a GLP-1 receptor agonist medication (such as semaglutide [Ozempic, Wegovy, Rybelsus], liraglutide [Saxenda, Victoza], or tirzepatide [Mounjaro, Zepbound]) perform resistance (strength) training before and after starting their medication.
GLP-1 medications are being prescribed more and more often to help people manage type 2 diabetes and lose weight. These medications work well, but a known side effect is that people can lose lean (muscle) tissue along with fat. Los...